Text Size

Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake (angiogenesis)

This study has been completed.
Sponsor:
Collaborator:
J~pharma
Information provided by:
Gunma University
ClinicalTrials.gov Identifier:
NCT00671242
First received: April 30, 2008
Last updated: May 2, 2008
Last verified: January 2008
History of Changes
  Purpose

Purpose: L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer (NSCLC).

Method: Thirty-seven NSCLC patients were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. Uptake of PET tracers was evaluated with standardized uptake value. VEGF, CD31, CD34, LAT1 and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical staining, and correlated with the clinicopathologic variables and the uptake of PET tracers.


Condition
Angiogenesis
Non-Small Cell Lung Cancer

Study Type: Observational
Official Title: Correlation of Angiogenesis With 18F-FMT and 18F-FDG Uptake in Non-Small Cell Lung Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by Gunma University:

Groups/Cohorts
I
L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer
Nuclear

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who underwent a thoracotomy within 4 weeks after 18F-FMT PET and 18F-FDG PET study
  • Histology is non-small cell lung cancer

Exclusion Criteria:

  • Patient who received neoadjuvant chemotherapy or radiotherapy before surgery
  • Patients who have insulin-dependent diabetes
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00671242

Locations
Japan
Gunma University Graduate School of Medicine
showa-machi, Maebashi, Gunma, Japan, 371-8511
Sponsors and Collaborators
Gunma University
J~pharma
  More Information

No publications provided by Gunma University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00671242     History of Changes
Other Study ID Numbers: kkaira1970
Study First Received: April 30, 2008
Last Updated: May 2, 2008
Health Authority: Japan: Institutional Review Board

Keywords provided by Gunma University:
Fluorine-18-α-methyltyrosine,
Positron emission tomography,
Fluorine-18-fluorodeoxyglucose,
Lung cancer,
 Angiogenesis
The median VEGF rate was 45% (range, 10-78%).
High expression was seen in 30 patients (81%, 30/37).
VEGF expression was statistically associated with progressively growing microvessel count.

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
 Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 23, 2013